RARECast
A podcast by RARECast - Thursdays
548 Episodes
-
How One Drugmaker Reaches out to Communities at Greater Risk for Rare Heart Condition
Published: 3/3/2023 -
A Next-Generation RNA Therapy Targets Telomere Disorders
Published: 3/3/2023 -
BridgeBio Advances Therapy for Limb-Girdle Muscular Dystrophy that Started with Two Patient Families
Published: 2/24/2023 -
Translating Urgency into Science
Published: 2/16/2023 -
Empowering Ultra-Rare Disease Patients to Pursue the Discovery of Treatments
Published: 2/10/2023 -
Why a Topical Cannabidiol Gel May Help Treat the Behavioral Symptoms of Fragile X
Published: 2/2/2023 -
An Ultra-Rare Disease Drug Developer Tries to Navigate Regulatory Uncertainty
Published: 1/26/2023 -
Powering Cells in People with Rare Mitochondrial Diseases
Published: 1/19/2023 -
Powering Weakened and Stressed Cells in ALS to Function Better with Nanocrystal Therapy
Published: 1/12/2023 -
Developing a New Class of Therapies Based on a Natural Cargo Carrier
Published: 1/5/2023 -
Reaching Beyond the Limits of Enzyme Replacement Therapies with Gene Therapies
Published: 12/29/2022 -
One Woman’s Journey as a Caregiver to a Husband with Frontotemporal Dementia
Published: 12/22/2022 -
Treating Rare Endocrine Disorders with Therapeutic Peptides
Published: 12/15/2022 -
Tackling the Pricing Challenges for Advanced Therapies for Rare Diseases
Published: 12/8/2022 -
Addressing the Current Limitations of AAV Gene Therapies
Published: 12/1/2022 -
Examining the Legislative Landscape for Rare Disease Drug Development
Published: 11/24/2022 -
How a Drug Setback Became a Patient Community’s Gain
Published: 11/18/2022 -
Helping Regulators and Drug Developers Understand the Challenges of Living with Fabry Disease
Published: 11/10/2022 -
Addressing Racial Disparities in a Rare Blood Cancer
Published: 11/3/2022 -
How New Sequencing Technology Promises to Alter the Diagnostic Odyssey
Published: 10/27/2022
RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.